Bioforce Nanosciences Holdings Inc. Quality Score
BFNH
Valuation is the primary weakness (avg 0/100). Growth is the relative bright spot.
Broad-market heuristics · Not a buy/sell signal
Valuation and growth
Valuation
Growth
Negative earnings, no valuation support
Above 10% CAGR, strong compounder
Business Quality & Capital Allocation
Heavy dilution above 5%
Expanded 3+pp, strong improvement
Net cash position, no leverage concern
Below 8%, may not cover cost of capital
Bioforce Nanosciences Holdings (BFNH) quality: score, margins and returns
Bioforce Nanosciences Holdings (BFNH) scores 40/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 5 metrics each scored 0 to 100. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is Bioforce Nanosciences Holdings (BFNH) a high-quality business?+
Bioforce Nanosciences Holdings scores 40 out of 100 on Intrinsiqq's quality score, a weighted blend of 5 metrics each scored 0 to 100, which rates it a mixed business on these measures. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does Bioforce Nanosciences Holdings's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from BFNH's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Bioforce Nanosciences Holdings scores well and where it falls behind.
SourceQuality score computed from the 10-Q filed 9 Nov 2026, covering the period ending 31 Dec 2026, as reported to the SEC. Data last refreshed 12 Nov 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Peers
Laboratory Analytical Instruments · Pick stocks to compare with BFNH
Spot a number that looks wrong? Check it in BFNH's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing BFNH
A free account gives you 10 stocks a day, a watchlist and price alerts.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.